Search - tctmd.com

Displaying 81 - 100 of 144

Sort: Relevancy | Date

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

News Conference News ESC 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

August 30, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Supplemental Oxygen Provides No Benefit to Patients With Suspected MI: DETO2X-AMI

News Conference News ESC 2017

Supplemental Oxygen Provides No Benefit to Patients With Suspected MI: DETO2X-AMI

Michael O'Riordan

August 28, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance

News Opinion Editor's Corner ESC 2016

My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance

September 08, 2016

News Conference News ESC 2016

Use of Antithrombotics Instead of Stents Appears Safe, Reduces Thrombus Burden in Subset of ACS Patients: EROSION

Michael O'Riordan

August 30, 2016

News Conference News ESC 2016

Prasugrel, Ticagrelor Give Similar Short-term Outcomes After Primary PCI: PRAGUE-18

August 30, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Conference News ESC 2016

Edoxaban Shows Safety, Efficacy for A-fib Patients Undergoing Cardioversion: ENSURE-AF

August 30, 2016

News Conference News ESC 2016

STICH Analysis by Age Shows Benefit of CABG in Ischemic Heart Failure Across the Decades

August 29, 2016

News Conference News ESC 2016

Screening for and Treating Asymptomatic Extracoronary Disease No Help in High-risk CAD

August 29, 2016

News Conference News ESC 2016

Treating Sleep Apnea Fails to Boost Outcomes in Patients With CVD: SAVE Trial

August 28, 2016

Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Heart Failure

Presentation ESC 2016

Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Heart Failure

Presenter: Javed Butler

August 28, 2016

News Conference News ESC 2016

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

August 28, 2016

News Conference News ESC 2016

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Michael O'Riordan

August 28, 2016

News Conference News ESC 2016

N-Acetylcysteine for Myocardial Salvage in STEMI? NACIAM Trial Treads Where Many Have Flopped Before

August 28, 2016

News Conference News ESC 2016

ICDs Do Not Reduce Mortality in Patients With HF Not Caused by Coronary Artery Disease: DANISH

Michael O'Riordan

August 28, 2016

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Presentation ESC 2016

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Presenter: Gilles Montalescot

August 28, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.